

Special Issue

Genetics and Epigenetics of Kidney Diseases

Message from the Guest Editors

Kidney diseases are a major health problem with increasing incidence, with serious impacts on patients' co-morbidities (mainly cardiovascular), and on patients' quality of life and survival, but also with a huge economic impact for caregivers. Both genomic and environmental factors contribute to the development of kidney diseases. The aim of this Special Issue is to bring together international experts to provide a comprehensive overview about this important and dynamic research field. Therefore, we invite you to participate by contributing either an original research article or a review focused on some aspects of this complex topic. Research areas may include (but are not limited to) genetics and epigenetics involved in the progression of chronic kidney disease, kidney stones, kidney malignancies, progression from acute to chronic kidney disease, development and progression of common causes of chronic kidney disease (e.g., diabetic kidney disease, polycystic kidney disease, vasculitis), but also in some rare genetic diseases such as atypical hemolytic-uremic syndrome and Fabry disease.

Guest Editors

Dr. Andreea Andronesi

Lecturer, Nephrology Department, Fundeni Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

Prof. Dr. Liliana Garneata

Associate Professor, Department of Internal Medicine and Nephrology, "Dr Carol Davila" Teaching Hospital of Nephrology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/116809

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).